Gemini Therapeutics (GMTX) Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular Degeneration
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- S&P, Nasdaq muted as bond yields rise; UnitedHealth boosts Dow
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- Bank of America profit hurt by losses on credit cards, office loans
- Morgan Stanley (MS) earnings beat lifts stock
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular Degeneration
February 8, 2021 7:00 AM EST- Business combination transaction with FS Development Corp., a special purpose acquisition company sponsored by Foresite Capital, completed on February 5, 2021
- Combined company renamed Gemini Therapeutics, Inc.
- Common stock commences trading today on the Nasdaq Global Market under ticker symbol GMTX
- Gross proceeds from this transaction totaled approximately $216 million, combining funds held in FS Development Corp.s trust account and a concurrent PIPE financing
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular... More
